Adverse event profile with once-monthly oral ibandronate: The MOBILE study long-term extension.

被引：0
|
作者：
Silverman, S.
Emkey, R.
Reginster, J. Y.
Lorenc, R.
Hughes, C.
Kendler, D.
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Radiant Res, Wyomissing, PA USA
[3] Univ Liege, B-4000 Liege, Belgium
[4] Childrens Mem Inst, Warsaw, Poland
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Univ British Columbia, Osteoporosis Res Ctr, Vancouver, BC V5Z 1M9, Canada
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [41] A PLACEBO-CONTROLLED STUDY OF EFFICACY AND SAFETY OF ARIPIPRAZOLE ONCE-MONTHLY FOR LONG-TERM MAINTENANCE TREATMENT IN SCHIZOPHRENIA
    Eramo, A.
    Fleischhacker, W. W.
    Sanchez, R.
    Perry, P.
    Jin, N.
    Johnson, B.
    McQuade, R. D.
    Carson, W. H.
    Kane, J.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [42] Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia
    Baker, R.
    Fleischhacker, W.
    Sanchez, R.
    Perry, P.
    Jin, N.
    Johnson, B.
    Forbes, R. A.
    McQuade, R. D.
    Carson, W. H.
    Kane, J. M.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 111 - 111
  • [43] Response to therapy with once-monthly ibandronate 150 mg: Post-hoc analysis of BMD responders from the mobile study
    Silverman, S. L.
    Hochberg, M.
    Cole, R. E.
    Barr, C. E.
    Genant, H. K.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S242 - S242
  • [44] Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
    Madera, Jessica J.
    Such, Pedro
    Zhao, Cathy
    Baker, Ross A.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 1593 - 1604
  • [45] Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
    Sliwa, Jennifer Kern
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Turkoz, Ibrahim
    Alphs, Larry
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2012, 8 : 375 - 385
  • [46] Daily and once-monthly oral ibandronate have similar safety profiles in elderly and younger women: 1-year results from the mobile study.
    Miller, P
    Lewiecki, M
    Sol, E
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S194 - S194
  • [47] Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
    El Khoury, Antoine C.
    Pilon, Dominic
    Morrison, Laura
    Shak, Nina
    Llaneza, Amanda
    Kim, Edward
    Lefebvre, Patrick
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 176 - 185
  • [48] Once-monthly oral ibandronate effectively normalizes biochemical markers of bone resorption in postmenopausal osteoporosis: MOBILE 2-year analysis.
    Miller, PD
    Kendler, DL
    Garnero, P
    Silverman, S
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Christiansen, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S284 - S284
  • [49] FRACTURE RISK IN WOMEN ≥65 YEARS WITH ONCE-MONTHLY ORAL IBANDRONATE COMPARED WITH WEEKLY BISPHOSPHONATES: SUBANALYSIS FROM THE EVALUATION OF IBANDRONATE EFFICACY (VIBE) DATABASE STUDY
    Silverman, S.
    Poston, S.
    Blumentals, W.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 153 - 153
  • [50] Aripiprazole once-monthly for long-term maintenance treatment of schizophrenia: a 52-week open-label study
    Peters-Strickland, T.
    Baker, R. A.
    McQuade, R.
    Jin, N.
    Eramo, A.
    Perry, P.
    Johnson, B.
    Duca, A.
    Sanchez, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S542 - S542
12345